Investor's Business Daily on MSN12h
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?
ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker.Please watch the video ...
HME News16h
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
MassDevice16h
ResMed revenue up 10% in Q2 — but GLP-1 questions remain
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...
ResMed upgraded to Buy at UBS as risks skew positive, consensus too cautious
UBS upgraded ResMed (RMD) to Buy from Neutral with a price target of $290, up from $255. The firm thinks consensus is too cautious in the ...
ResMed stock holds as Oppenheimer maintains Perform rating
Oppenheimer analysts maintained a Perform rating on ResMed (NYSE:RMD) following the company's financial results for the ...
Resmed (RMD) Receives a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Resmed (RMD – Research Report) today and set a price target of $250.00. The ...